Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B. The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study. AO [Internet]. 2015 Feb. 7 [cited 2026 May 20];54(2):164-70. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/25812